GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » YoY EPS Growth

NervGen Pharma (STU:9UA) YoY EPS Growth : 15.53% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is NervGen Pharma YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. NervGen Pharma's YoY EPS Growth for the quarter that ended in Dec. 2024 was 15.53%.

NervGen Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was €-0.09.

NervGen Pharma YoY EPS Growth Historical Data

The historical data trend for NervGen Pharma's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NervGen Pharma YoY EPS Growth Chart

NervGen Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial 13.46 1.78 -22.62 4.06 7.31

NervGen Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.28 50.91 -33.93 2.08 15.53

NervGen Pharma YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

NervGen Pharma's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(-0.241--0.26)/ | -0.26 |
=7.31 %

NervGen Pharma's YoY EPS Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EPS Growth (Q: Dec. 2024 )
=(Earnings per Share (Diluted) (Q: Dec. 2024 )-Earnings per Share (Diluted) (Q: Dec. 2023 )) / | Earnings per Share (Diluted) (Q: Dec. 2023 )) |
=(-0.087--0.103)/ | -0.103 |
=15.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NervGen Pharma YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of NervGen Pharma's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

NervGen Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NervGen Pharma Corp (STU:9UA) » Definitions » YoY EPS Growth
Comparable Companies
NEOE:CYBN TSX:FRX TSX:EPRX XCNQ:METX TSX:TH TSXV:ARCH TSX:MSCL XCNQ:DRUG TSX:MDNA XCNQ:GLAB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
NGENF:USA NGEN:Canada
Address
112-970 Burrard Street, Unit 1290, Vancouver, BC, CAN, V6Z 2R4
Website
https://www.nervgen.com
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.

NervGen Pharma Headlines

No Headlines